#UK-based portal for CBD news | Explore Tumblr posts and blogs

canexuk · 4 years ago

Text

Almost Half of People in the UK are Unaware that Medical Cannabis is Legal

Sheffield, UK, October 2020 – Despite being legal in the UK for almost two years, access to medical cannabis and awareness among the public remains surprisingly low. So, we decided to put together a simple guide of how access to medical cannabis currently works.

Legalising Medical Cannabis

Cannabis was rescheduled (from schedule 1 to schedule 2 of the Misuse of Drugs Act 1971) in 2018 to allow for the medical application of the drug. This major decision was largely influenced by the high-profile cases of two children who suffer from rare forms of treatment-resistant epilepsy.

The parents of Billy Caldwell and Alfie Dingley had tried a number of registered epilepsy medications with little success until they discovered the positive effects of cannabis-based medications. However, the legality of these drugs in the UK meant that they had to source medications from abroad.

The rescheduling of cannabis allowed for specialist clinicians in the UK to prescribe medical cannabis products. Following this decision, medical cannabis is now legal for the first time in almost 50 years.

Accessing Medical Cannabis

Despite the rescheduling of cannabis, access to medical cannabis through the NHS remains practically non-existent. Many critics of the current guidelines believe that this is largely down to the restrictive recommendations made by the National Institute of Health and Care Excellence in November 2019.

In theory, patients should now be able to access medical cannabis products for a small number of conditions. These include treatment-resistant epilepsy, spasticity associated with multiple sclerosis, and chemotherapy-induced nausea and vomiting. However, NHS prescriptions for medical cannabis products – even for these conditions – remain critically low, if not non-existent.

Medical cannabis clinics, however, have been opening around the nation with the aim of plugging the gaps in patient access. Sapphire Medical Clinics has launched a number of schemes and initiatives over the last couple of years in an effort to aid in the progression of the UK’s medical cannabis sector. These include the Sapphire Foundation which helps to remove financial barriers to patients and the UK Medical Cannabis Registry which collects real-world evidence on medical cannabis prescribing.

Progressing Medical Cannabis Access in the UK

The data collected through our ongoing Canex poll support calls for increased education on medical cannabis – for both medical professionals and the public – in the UK. Despite numerous countries, including the UK, having now legalised medical cannabis, the potential mechanisms of cannabinoids and the endocannabinoid system is still not taught in medical curriculums.

This has led to a limited number of doctors having sufficient knowledge of medical cannabis and how it could potentially benefit a huge array of conditions. A number of initiatives are now aiming to address this problem, including the Sapphire Institute which provides an online training and up-to-date research on medical cannabis.

Medical cannabis registries like the UK Medical Cannabis Registry and Drug Science’s Project Twenty21, aim to collect the evidence needed to support the progression of medical cannabis prescriptions in the UK.

About Company:

We are Canex – the leading UK-based portal for CBD news. With the CBD industry exploding all around the world, we aim to bring you everything you need to know – from both home and abroad. The CBD industry has become one of the fastest growing health and wellness industries in recent years. We provide the most up-to-date information about the industry, in order to keep the general public well-educated in line with this growth.

#UK-based portal for CBD news #Medical Cannabis Registry #medical cannabis products

0 notes

theclavon2-blog · 4 years ago

Text

Clavon Condo

Clavon is proudly presented to you by United Venture Development (Clementi1) Pte Ltd, a joint venture of residential development between niche developer UOL Group Limited (UOL) and United Industrial Corporation (UIC). Both the developers are Singapore’s leading public-listed property companies wide an extensive portfolio of property development and investment. UOL Group was founded in 1963, is one of the top public listed property firms in Singapore. With more than 30 years of strong presence in both local and overseas market. UOL has constantly developing and managing shopping malls, residential properties, office towers and hotels. UOL is determined to build iconic buildings of its own class and distinction as we believe we should go beyond providing a luxury living environment. Some of our past portfolio include Archipelago, Avenue South Residence, Clement Canopy, Meyer House, Riverbank @ Fernvale, The Tre Ver, Principal Garden and many other more. UIC was also founded in 1963 and thereafter public listed in 1971. The group’s main business is property development and investment. UIC has become one of the largest property developer in Singapore after the acquisition of Singapore Land Limited in 1990 . We have strong presence in various parts of China, Malaysia and in UK London. Our Singapore's portfolio includes Mon Jervois, V On Shenton and The Clement Canopy. Clavon pricing is yet to be announced. It will be attractively priced for all registered early-bird buyers. The developers will announce when the Clavon Showroom is ready for viewing. Do register early as developer's VVIP guest for 1st hand information such as Clavon Floor Plan, Clavon E-brochure and Clavon Pricing. VVIP Guest will be invited for the 1st day Preview Launch with attractive developer discount. Clavon is superbly located along Clementi Avenue 1 in the popular matured Clementi Estate. This brand new development is just 10 minutes’ leisure stroll to the Clementi MRT. We are just 1 MRT station away to the Jurong East Regional Centre, the 2nd CBD in Singapore. It provides great convenience for the residents of the Clavon with excellent connectivity to their work places such as Marina Bay Financial Centre(MBFC). One-North, Biopolis, Fusionopolis Mediapolis and Jurong Innovation District via public transport or driving. For those who uses private transport, Clavon Singapore is within close proximity to Pan-island Expressway (PIE) & Ayer Rajah Expressway (AYE), which is only 5 minutes’ drive from the condo. Clavon will benefit from the rejuvenation of the of Jurong Lake District, Singapore’s 2nd CBD with more upcoming recreational activities and amenities. Owners of Clavon Condo can look forward to the upcoming Jurong Regional Line and High Speed Rail for more convenience and accessibility to all parts of Singapore. Parents who are looking for reputable Primary School for enrolment, you may consider the popular and highly sought after Nan Hua Primary School, Clementi Primary School, Pei Tong Primary School, Henry Park Primary School, Qifa Primary School. Other tertiary institutions are National University (NUS), NUS High School of Mathematics and Science, Singapore Polytechnic and Ngee Ann Polytechnic. Clavon Condo has great surrounding amenities such as 321 Clementi, Clementi Mall, Jem, West Gate, IMM, JCube, Big Box, Jurong Point and many other more where you can explore at Clavon Location Map. For Clavon Showflat Viewing Appointment, please kindly register an appointment through this website or simply call our sales Hotline +65 61009266 prior making your way down to our Clavon Showroom. Due to regulation of crowd control, Clavon showflat will not be open to the public but via APPOINTMENT only. Therefore it is strongly advisable to secure an appointment online before coming over. For those who had registered online, you will be guaranteed of Getting the Best Direct Developer Price & Discounts with absolutely NO COMMISSION payable by you. If you had registered an online appointment with us, you do not have to register again to avoid duplication. Please be rest assured that our sales staff will contact you in One hour time to confirm your appointment. An email will also be sent to you once registered with us. We are currently in the early phase of Registration of Interest for Clavon VVIP Preview. Register your Interest early to be the first to view our beautiful Showflat once its ready for viewing. We will update Clavon Balance Units Chart and Clavon Pricing in this official website once the project is launched. Please do note that all balance units for sale at Clavon Condo are based on first come first serve basis. We do allow reservation of unit up to 2 hours and it is subject to management’s approval. Price stated in this portal is subjected to change without any further notice. Please do not miss this rare new condo launch near Clementi MRT by UOL & UIC. Only 640 exclusive units are available. Register now for Clavon VVIP Preview today

1 note · View note

evoldir · 3 years ago

Text

Fwd: Graduate position: UStAndrews.CrowToolEvolution

Begin forwarded message: > From: [email protected] > Subject: Graduate position: UStAndrews.CrowToolEvolution > Date: 21 October 2021 at 09:30:07 BST > To: [email protected] > > > > > PHD: TOOL CRAFTING IN NEW CALEDONIAN CROWS > > A fully-funded PhD studentship for research on New Caledonian crows is > available in Professor Christian Rutz’s group at the University of St > Andrews, UK (deadline: 03 December 2021). A summary is provided below, > and the full advert can be found on FindAPhD: > > https://ift.tt/3k3xElp > > > SUMMARY > > New Caledonian crows are renowned for their ability to manufacture > complex foraging tools from plant materials. For example, using an > elaborate sequence of actions, they craft hooked stick tools from > branching vegetation, and employing completely different techniques, > they cut a variety of tool shapes from the barbed edges of screw-pine > leaves. Professor Christian Rutz’s research group has been studying > the behavioural ecology of New Caledonian crows since 2005, focussing > on seven established study sites. Building on some of the group’s > recent advances, this PhD project will provide a detailed investigation > of the tool-manufacture behaviour of wild crows. There is considerable > flexibility with regards to specific study objectives, but the successful > candidate is likely to conduct both field observations and aviary-based > experiments with temporarily captive subjects, with excellent scope for > collaboration with other group members and external project partners. > This fully-funded PhD project offers exciting opportunities for a highly > motivated student to join a dynamic research group, to conduct topical > research on the behavioural ecology of one of the most accomplished > non-human tool users, and to receive training in state-of-the-art > field-ornithological research methodologies. > > CENTRE FOR BIOLOGICAL DIVERSITY > > The Centre for Biological Diversity (CBD) at the University of St > Andrews provides a highly interactive and stimulating environment > for doctoral students, with particular strengths in animal behaviour > and evolution. The successful candidate would benefit from frequent > interactions with postgraduates, postdocs and PIs, including lab chats, > seminars, and discussion groups. > > CONTACT > > Please address any inquiries, with CV and a cover letter outlining > your interest in the position, to Professor Christian Rutz > ([email protected]). Before you get in touch, please > consult the references listed below, to get a good understanding of the > group’s current research activities. All formal applications must be > made through the university’s Online Application Portal (see below). > > SELECTION CRITERIA > > + outstanding academic track record > > + excellent analytical, writing and communication skills > > + demonstrable skill and enthusiasm for behavioural research and > fieldwork > > + high degree of self-motivation and independence > > + ability and willingness to live and work overseas, for extended > periods of time and sometimes under challenging field conditions > > + clean driving licence > > + prior research experience is an advantage > > + basic French language skills are an advantage > > HOW TO APPLY > > Please make a formal application to the School of Biology through our > Online Application Portal: > > https://ift.tt/3vJ5mnH > > We require the following documents: CV, personal statement, 2 references, > academic qualifications, English language qualification (if applicable). > > Keywords: Animal Behaviour, Behavioural Ecology, Evolutionary Ecology, > Animal Cognition, Tool Use, Social Learning, Cultural Evolution > > FUNDING NOTES > > Funded PhD Project (UK and international students (including EU)). > > Funded by the School of Biology, University of St Andrews. The studentship > covers tuition fees (Home and Overseas) and a living allowance for a > duration of 3.5 years. > > REFERENCES > > Hunt GR (1996) Manufacture and use of hook-tools by New Caledonian > crows. Nature 379, 249-251. > > Hunt GR, and Gray RD (2003) Diversification and cumulative evolution in > New Caledonian crow tool manufacture. Proc. R. Soc. B 270, 867-874. > > Hunt GR, and Gray RD (2004) The crafting of hook tools by wild New > Caledonian crows. Proc. R. Soc. B (Suppl. 3) 271, S88-S90. > > Hunt GR, and Gray RD (2004) Direct observations of pandanus-tool > manufacture and use by a New Caledonian crow (Corvus > moneduloides). Anim. Cogn. 7, 114-120. > > Kenward B, Weir AAS, Rutz C, and Kacelnik A (2005) Tool manufacture by > naïve juvenile crows. Nature 433, 121. > > Klump BC, Cantat M, and Rutz C (2019) Raw-material selectivity in > hook-tool-crafting New Caledonian crows. Biol. Lett. 15, 20180836. > > Klump BC, Sugasawa S, St Clair JJH, and Rutz C (2015) Hook tool > manufacture in New Caledonian crows: behavioural variation and the > influence of raw materials. BMC Biol. 13, 97. > > Rutz C, Hunt GR, and St Clair JJH (2018) Corvid technologies: how do > New Caledonian crows get their tool designs? Curr. Biol. 28, R1109-R1111. > > Rutz C, and Hunt GR (2020) New Caledonian crows afford invaluable > comparative insights into human cumulative technological > culture. Behav. Brain Sci. 43, E177. > > Rutz C, Klump BC, Komarczyk L, Leighton R, Kramer J, Wischnewski S, > Sugasawa S, Morrissey MB, James R, St Clair JJH, Switzer RA, and Masuda BM > (2016) Discovery of species-wide tool use in the Hawaiian crow. Nature > 537, 403-407. > > Rutz C, and St Clair JJH (2012) The evolutionary origins and ecological > context of tool use in New Caledonian crows. Behav. Processes 89, 153-165. > > Rutz C, Sugasawa S, van der Wal JEM, Klump BC, St Clair JJH. 2016 Tool > bending in New Caledonian crows. R. Soc. Open Sci. 3, 160439. > > St Clair JJH, Klump BC, Sugasawa S, Higgott CG, Colegrave N, and Rutz > C (2018) Hook innovation boosts foraging efficiency in tool-using > crows. Nature Ecol. Evol. 2, 441-444. > > St Clair JJH, Klump BC, van der Wal JEM, Sugasawa S, and Rutz C > (2016) Strong between-site variation in New Caledonian crows’ use of > hook-tool-making materials. Biol. J. Linn. Soc. 118, 226-232. > > St Clair JJH, Rutz C (2013) New Caledonian crows attend to multiple > functional properties of complex tools. Phil. Trans. R. Soc. B 368, > 20120415. > > Steele MP, Neaves LE, Klump BC, St Clair JJH, Fernandes JRSM, Hequet V, > Shaw P, Hollingsworth PM, and Rutz C (2021) DNA barcoding identifies > cryptic animal tool materials. Proc. Natl Acad. Sci., USA 118, > e2020699118. > > Sugasawa S, Klump BC, St Clair JJH, and Rutz C (2017) Causes > and consequences of tool shape variation in New Caledonian > crows. Curr. Biol. 27, 3885-3890. > > > Christian Rutz > via IFTTT

0 notes

pharmaphorumuk · 5 years ago

Text

Addressing the medical cannabis knowledge gap

The legalisation of medical cannabis in November 2018 was hailed as a landmark victory for the British medical industry, with scientists, researchers and patients alike all welcoming the change in law. However, whilst many took this as the beginning of a new progressive era in modern medicine, the reality is far removed.

Today regulations around the use and supply of medical cannabis remain vague and prescriptions are scarce. In fact, at the end of May 2019, Seema Kennedy, a public health minister, claimed that only six NHS prescriptions had been issued since the re-scheduling, with just ten private prescriptions issued between January and February 2019. This is despite there being over 80,000 UK doctors who are certified to prescribe medical cannabis.

For the handful of patients who have managed to obtain NHS prescriptions, many have had their access restricted by local clinical commissioning groups, on the basis that there is insufficient evidence for its efficacy, and many NHS trusts are refusing to honour prescriptions.

There is a clear gap between policy and implementation, and a noticeable need for cannabis education for healthcare professionals.

“The NICE guidelines expected in October could be a real game changer in providing the right support system and information portal for HCPs”

Unfortunately, not only does the cannabis knowledge gap mean health care professionals (HCPs) are holding patients back from potentially helpful options — such as medical cannabis — for treatment and pain management, but it also inhibits patients from getting the education they need to make informed decisions about their health.

Apprehensions remain from many of the health professionals who act as gatekeepers between the patient and medical cannabis. Increasingly, these apprehensions do not come from a wholesale rejection of cannabis as a medicine, but from a clear desire to better understand the intricacies of the drug before putting their signature to a prescription.

HCPs are currently relying on the interim guidelines issued by the Royal College of Physicians (RCP) and the British Paediatric Neurology Association (BPNA), which some have dubbed ‘unnecessarily restrictive’, ultra-cautious and open to interpretation, despite the health benefits claimed by users of medical cannabis

However, experts are used to having significant quantities of data from randomised control trials (RCTs) when they are drafting new guidelines.

To help combat this, in October 2019, the National Institute for Health and Care Excellence (NICE) will publish new guidelines, which may provide doctors with the information they need to confidently prescribe the drug.

Why is there a knowledge gap?

Little research has been done so far on the medicinal properties of cannabis given it was solely classified as a Class A drug until November 2018. This means there are currently no restrictions on the type of product that can be prescribed, apart from that it can’t be smoked.

HCPs are uncertain about the side effects and some of their perceptions stem from the drug’s legacy and negative cultural associations. Consequently, there is undeniably a lack of experience and training on the use and the evidence for Cannabis-Based Medicinal Products (CBMPs) within the medical community even at the specialist level.

Knowledge is disparate and often associated with a single condition or CBMP. Some of the largest gaps exist between current and desired knowledge of dosing and efficacy, the development of treatment plans, cannabis’ interaction with other medications, and the long-term impact of prolonged use on cognition and brain development.

Simply put, cannabis is not a “one size fits all” solution. There are a range of medical cannabis products available with varying cannabinoid profiles, with most currently focused on THC and CBD.

Building on this ambiguity, all cannabis-based products for medical use, except for Sativex, are unlicensed and can only be prescribed on a case-by-case basis by a physician once all other avenues have been exhausted.

Medicine of the last resort

There are two crucial issues at play here.

Firstly, that HCPs are being advised to only consider medicinal cannabis as a ‘last resort’ when in fact it may be the best treatment option available for a given condition. And secondly, as the drugs are un-licensed, doctors are not insured to issue prescriptions. Therefore, if a patient were to have a reaction, the doctor, or the trust the doctor works for, could be liable.

Unfortunately, because of this personal risk involved, many HCPs are reluctant to endorse medicinal cannabis until there is greater clarity surrounding the guidelines and evidence provided.

This is a travesty because there is vast anecdotal evidence that suggests medical cannabis has the potential to greatly improve and transform a number of patients lives. From treating seizures in childhood epilepsy and chemotherapy-induced nausea to alleviating symptoms in MS and easing chronic pain in adults, many patients have reported notable improvements upon switching their traditional treatment plans for medicinal cannabis.

Whilst multiple anecdotal stories can start to equate to a pattern of evidence, there are concerns regarding the quality of this evidence among HCPs. This is primarily regarding the potential of a direct link between cannabis use and psychosis.

Although there haven’t been any RCTs to warrant the argument that there is a causal relationship, guidelines from the Royal College of General Practitioners at the end of 2018 suggest that cannabis can trigger symptoms of psychosis in individuals who are schizophrenic or have a family history of psychosis.

However, whilst some studies claim that cannabis use can induce schizophrenia, the percentage of people diagnosed with the disorder has remained consistent. At a time when cannabis use is at an all-time high across the globe, these statistics don’t seem to add up. And whilst cannabis may cause temporary psychosis, so can caffeine, alcohol and nicotine. Whether it can directly trigger schizophrenic episodes is still up for debate.

A clearer understanding of the key elements of the cannabis flower is required, beginning with the key distinction between psychoactive and non-psychoactive compounds. THC is psychoactive, meaning it alters perception and thinking, while CBD is not. While THC is widely recognised for its recreational contribution, it also makes a significant medical contribution.

Cannabis is no magic bullet for everyone with one or more health issues. But for some people, it can be medicinally very beneficial.

Future landscape

The uncertainty and confusion amongst the medical community aptly demonstrates why there is a need for greater clinical and legislative knowledge surrounding medical cannabis backed by concrete science and studies.

In fact, The Commons Health and Social Care Committee has even suggested that ministers failed to clarify the practicalities of its medical cannabis legislation and this has left health care professionals at a loss.

Despite these acknowledgements, Matt Hancock, the health secretary, told MPs last month that medical cannabis will not need to be tested through RCTs in the UK in order to be licensed. Speaking at the Health and Social Care Select Committee, Hancock suggested that because the licensing process considers global evidence, localised trials will not be required. However, in spite of this the government funded National Institute for Health Research has already put in two calls for trial funding.

With confusion and mixed messages at every turn it is no surprise that medical practitioners are at a loss.

The National Institute for Health and Care Excellence (NICE) guidelines expected in October could be a real game changer in providing the right support system and information portal for HCPs.

Encouraging greater uptake among HCPs won’t happen overnight given the size and complexities of the NHS and knowledge transfer will be a gradual process.

Drawing on Canada’s experience many doctors do not, and even after a decade or more will not, prescribe CBMPs. However, a minority will, and the key to building a system of coverage that offers meaningful access is to connect those doctors to the larger pool of patients.

All medicine is, or should be, evidence based. As a natural product, medical cannabis does not entail the same approval process as synthetic drugs, but the industry depends and will continue to depend on research and evidence to support claims. This will enable HCPs to prescribe medical cannabis with confidence and a solid knowledge base.

At the end of the day, HCPs are regarded as trusted experts in society with access to portals of information, so they need education, evidence and the ability to share best practice based on their experiences

The transition of the growing acceptance of cannabis’ medical application and benefits provides an opportunity to develop and implement evidence-based education for HCPs. This should address the existing perceived knowledge gaps by collecting and disseminating information about the effectiveness of medical cannabis across qualifying conditions, evaluate the effectiveness of such strategies on clinical practice and, ultimately, on health outcomes.

About the author

Marc Davis is the president of Capital Markets Media (CMM) and co-founder of the Women, CBD and Medical Cannabis Conference. A former journalist and venture capitalist, he is regarded as a highly knowledgeable global cannabis expert and has worked with the biggest names in the cannabis industry, including Aurora Cannabis, Canopy Growth, Aphria, The Green Organic Dutchman, HEXO Corp. and iAnthus Capital.

The post Addressing the medical cannabis knowledge gap appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/views-analysis-market-access/addressing-the-medical-cannabis-knowledge-gap/

0 notes

sustainhealthmagazine · 5 years ago

Text

Five wellness trends to expect in 2020

(adsbygoogle = window.adsbygoogle || []).push({});

By HEALTH EDITOR FOR SUSTAIN HEALTH

PUBLISHED: 14:12, 02 December 2019 | UPDATED: 14:42, 02 December 2019

This year, the likes of CBD oil, rowing workouts and wellness retreats dominated the wellness landscape, but what does the world of wellness have in store for 2020?

(adsbygoogle = window.adsbygoogle || []).push({});

In the last five years, the health and wellness market in the UK has increased by 18%, rising from £17bn to £21bn.

Below, the leading health and wellness booking app, MINDBODY reveals the five trends worth trying in 2020.

1. Holistic Training

The holistic approach to training takes everything into account including your physical, mental, and emotional health. In short, you place priority on your diet and lifestyle factors as well as your exercise routine.

Today, the fitness industry has shifted its focus from the overall appearance of our bodies to our wellbeing and mental health. In fact, according to MINDBODY research one in three UK men now join the gym to build muscle but continue to attend for the benefit of their mental health. What’s more, facilities dedicated solely to wellness are also on the rise. For example, Mindset integrates mindfulness into their product offering which is promoted throughout each session to help transform both the mindset and overall wellbeing of attendees.

So, if you’re looking to change your fitness routine in the new year, contemplate taking a more holistic approach. Consider yoga or meditation to help minimise physical and emotional stress or try new activities and meet new people to balance your lifestyle. Also look to incorporate more healthy, nutritious foods into your diet. You’ll soon notice a difference in both your emotional and physical health.

2. Boutique Fitness outside of the Capital

Boutique fitness is on the rise! Boutique studios tend to specialise in a particular type of fitness (such as yoga, functional training, or high-intensity interval training) and are often more intimate than traditional gyms and fitness centres, with a greater focus on group exercise.

It's no secret London has always led the way when it comes to the adoption of the fitness industry and is often the first city to introduce new facilities, classes and the like. However, according to the latest usage data from MINDBODY, outside of London a huge 119,567 bookings were made each month, Manchester booked the highest number of classes outside of the capital - over 10,700 (up 3,000 from the start of the year), followed by Birmingham (8,706), Glasgow (5,900), Bristol (4,616) and Reading (3,987). It’s very clear fitness is vastly spreading outside of the capital, with cities such as Manchester, Birmingham and Glasgow now home to boutique studios.

What’s more, UK gym-goers are also prepared to pay 20% more for this premium fitness service4, so the consumer demand points towards further growth in 2020 and beyond.

(adsbygoogle = window.adsbygoogle || []).push({});

3. On Demand Fitness

Home-based workouts started to become popular in 2018 and are seeing increased attention and popularity, so they will likely be a prominent trend in 2020. The likes of Peloton, BoxVR and Fiit allow people to live-stream workouts from the comfort of their home. Moreover, platforms such as YouTube also offer people free, home-based workouts with and without equipment.

Working out from home has multiple benefits such as convenience and privacy, plus it can help to save both time and money. However, the community aspect of in-studio workouts remains a top driver for gym attendance. MINDBODY research found that half of Britons (50%) say having a workout 'buddy' helps increase fitness motivation5.

Due to the changing landscape of how we work, with more travel, flexible and remote working, we can expect to see our favourite gyms and studios to embrace technology in 2020 to increase their fitness footprint beyond their physical environment to accommodate their member’s schedules and needs. Think online streaming for a hotel workout or an online portal, whereby you can connect with your trainer wherever you are in the world.

4. Recovery

With HIIT dominating studio timetables the last few years, it was inevitable that our bodies were going to start fighting back and crave more rest and recovery. With the increase of in-studio technology, such as FitMetrix, we can get access to more data around our workouts and the effort that we exert in each class, therefore we know which days we should be pulling back and when we should be going all out.

This ‘new’ information that we get access to as consumers means we can train smarter and maximise our ‘recovery days’. According to MINDBODY booking data, Cryotherapy has seen an increase of 162% in bookings, along with Water Therapy (107%). Both of these methods of recovery are still not widely accessible, so you can expect more gyms and establishments to create partnerships with Wellness centres specialising in these forms of recovery for their members to benefit from a more well-rounded routine.

What we’re doing between the sheets is also a hot topic, and rightly so! Getting quality sleep is also an essential part of recovery and being deprived of those all-important Z’s can lead to negative effects on blood pressure, hormonal imbalance, muscular recovery and injuries.

There are plenty of apps designed to help you get an excellent night sleep, such as Headspace and Pzizz, which use calming music and sound effects designed using the latest clinical research.

In 2020 will we take it a step further and start encouraging sleep during the day? Some companies have made it standard practice to allow naps in the quest to boost wellbeing, whilst pop up nap bars have been well received in London and some studios have experimented with scheduling ‘napping classes’ on their timetables.

5. Plant-based

Following the recent worldwide release of ‘The Game Changers’, a revolutionary new film about plant-based eating, search interest for ‘plant-based diets’ in the UK increased by a staggering 465%. What’s more, we’ve also seen high street brands like Gregg’s explore meat-free dishes with the launch of its vegan sausage roll, and McDonald’s vegan burger in Germany, with a UK launch, possibly not too far away.

Nutrition and health expert, Plamena Dincheva (NCFE Cache Level 2 – Nutrition and Health), says: “If you’re looking to introduce a plant-based diet in the new year, consider incorporating cruciferous vegetables including broccoli, cauliflower, kale, pak choy, cavelo nero and cabbage. Cruciferous veg contains a phytochemical called ‘sulforaphane’ that upregulates a master regulator gene called NRF2. This, in turn, switches on a cascade of 100 other genes that are cell- protective.

“If you’re not ready to go completely plant-based in 2020, then I advise you aim to include more vegetables with every meal instead. It is, however, important to remember that eating meat and fish is still very healthy and some proteins can only be found in meat!”

Richard Martinson, Wellness Specialist at MINDBODY also comments: “Mental and physical recovery methods such as meditation, massages, water therapy, and cryotherapy are all expected to remain popular throughout 2020 as people look to balance their busy lives and exercise regimes with proper rest and recovery. Come the new year, many people will be looking to shake up their wellness routines and the five trends we’ve discussed here offer a varied, exciting mix of new things to try.

“However, it’s important to remember that everyone has their individual preferences when it comes to wellness, so the trends we’ve pulled together here may not appeal to everyone. If this is the case, our advice is to simply identify an area of your wellness that you’d like to improve, do a little bit of research around it, and set yourself achievable targets.”

For more information, visit uk.mindbodyonline.com

(adsbygoogle = window.adsbygoogle || []).push({});

READ NEXT

#bottom line

0 notes

moxxart · 8 years ago

Text

We’ve all tweaked our backs, (shoulders or knees) at some time in our life, right?

Some of us go to the doctor, the chiropractor or our acupuncturist but often times even the most holistic practitioners may see us in such pain that even they may suggest or prescribe a first-line treatment, such as acetaminophen (the active ingredient in Tylenol, and other brands) but you know it is just about useless when it comes to relief of low back pain and that was the conclusion Australian researchers came to in a review of clinical trials published in the British Medical Journal in 2015. However, when acetaminophen fails to bring relief, often a patient’s next step is to take non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin, but are these effective at reducing back pain?

No, actually they aren’t. A new review by the same research group finds that even anti-inflammatories offer little benefit to back pain sufferers.

Here are the details:

Only one patient in six is helped

For their review, the George Institute for Global Health based at Sydney Medical School examined 35 trials involving over 6,000 patients taking NSAIDs.

Results were published in Annals of the Rheumatic Diseases on the 2nd of February, 2017.

The researchers found that only one patient out of six achieved significant pain reduction. The article concluded that these drugs “provided clinically unimportant effects over placebo.”

Also – a well-known side effect — this class of drug increased the risk of gastro-intestinal reactions such as bleeding or stomach ulcers by 2½ times. In the United States, more than 16,000 people a year die of NSAID-related causes, mostly gastrointestinal, according to a 1999 study.

Associate Professor Manuela Ferreira, lead author of the Sydney study, said “…our results show anti-inflammatory drugs actually only provide very limited short-term pain relief. They do reduce the level of pain but only very slightly, and arguably not of any clinical significance.

“If you consider the side-effects, which are important, we argue that the benefit is not really worthwhile.”

Fellow study author Gustavo Machado added, “Millions are taking drugs that not only don’t work very well, they’re causing harm. We need treatments that will actually provide substantial relief of these people’s symptoms.

“Better still, we need a strong focus on preventing back pain in the first place. We know that education and exercise programs can substantially reduce the risk of developing low back pain.”

Treating back pain without drugs

There are a number of alternatives if you’re seeking drug-free pain relief. These include visiting a therapeutic massage or zero balancing therapist, an acupuncturist or good chiropractor and it is even possible that you might get lucky and find one who has incorporated a new European medical device into their protocols which is called BEMER.

You can see the BEMER’s luxurious slate grey full body length B-Body mat installed on this recliner below. Off to the side on the floor is the BEMER B-box or control box. All we do is push the start button and recline on the mat and relax for 8 minutes while the FDA registered class one, medical device which holds 5 international patents helps the body to heal itself. The BEMER multi-dimensional wave signal enhances general blood flow, the bodies nutrient & oxygen supply, waste disposal, cardiac function, physical fitness, endurance, strength, and sleep management. There are no side effects, only side benefits!

Take a look at this animated video to get an idea of how BEMER can help you.

If you want a do-it-yourself solution or want to support your BEMER sessions, try the safe anti-inflammatories derived from nature, such as Omega 3 from organic Green lip Mussels such as MOXXOR, which is my first choice or a bundle of products that contains a blend of ingredients such as those found in Joint Health Formula, ProLyt, Tissue Repair and Immune Assist. All of these can be taken together or in any combination you choose, just follow directions on the label. A good idea is to take the supplemental protocol 20 minutes before your BEMER session.

You might also consider supporting your BEMER session with CBD Oil. See this article on how this might be an excellent support strategy again with the BEMER to help your body heal itself. I think the folks in this article would have had a better result with BEMER. I have used CBD and THC oils for over two years now as it helped me though my personal journey with cancer and into remission. I recommend doing a consultation with a Cannabis nurse to get clear directions.

The lady in the photo below is seen just reclining on the BEMER B-Body mat and all she did was press the start button to the intensity and or program I will instruct you personally to use when we work together when your new BEMER Pro arrives.

Here is an excellent presentation by a chiropractor regarding BEMER and how microcirculation when enhanced can help the body to heal itself and I have seen this first hand to be true. Your BEMER Pro will come with a full complement of attachments for spot treatments including the red light attachment for conditions close to the skin surface.

Above is the B-Sit which is an optional attachment which I love to sit on, use behind my back or even o the floor for my feet.

To prevent back pain, see if the following procedures help to support your BEMER sessions:

Lose excess pounds. The gut hanging over your belt is a huge strain on your spine.

Stay mobile. Take regular daily walks.

Vary your sleep position to include both your sides and back. Don’t lie on your chest as this strains the neck and lower back. Sleep on a medium-to-firm mattress (not too soft or too hard).

Adopt a good sitting posture with thighs sloped slightly downward. Desk chairs should mold to support the lower back. Sit with tops of ears in line with shoulders. Take regular breaks when sitting.

Improve posture and help prevent back pain by exercises that promote balance, strength and flexibility in the spine. Straighten Up UK is a series of gentle daily exercises that takes less than 7 minutes (see references below). Many people also find yoga helpful.

With regular twice daily 8 minute BEMER sessions morning and night, attention to strategies like those above, back pain episodes should occur less and less frequently. Hopefully, they will disappear altogether. As always when you purchase your BEMER Device through me at my BEMER website, I am here to be of help! Just email me at [email protected] and or through my website portal at http://www.artofwellness.bemergoup.com

References:

https://www.ncbi.nlm.nih.gov/pubmed/25828856

http://ard.bmj.com/content/early/2017/01/20/annrheumdis-2016-210597.short?g=w_ard_ahead_tab

https://chiropractic-uk.co.uk/straighten-up-uk

Got Back Pain? Drugs are not Much Help! We’ve all tweaked our backs, (shoulders or knees) at some time in our life, right? Some of us go to the doctor, the chiropractor or our acupuncturist but often times even the most holistic practitioners may see us in such pain that even they may suggest or prescribe a first-line treatment, such as acetaminophen (the active ingredient in Tylenol, and other brands) but you know it is just about useless when it comes to relief of low back pain and that was the conclusion Australian researchers came to in a review of clinical trials published in the

#accupuncture #acupuncturists #Back #cardiovascular disease #chirorpractors #circulation #discomfort #hips #knees #massage therapists #massage therapy #physical fitness #physical therapists #shoulders #strength

0 notes

canexuk · 4 years ago

Text

Will Brexit be a Golden Opportunity for UK-Based CBD Businesses?

Although the United Kingdom left the European Union on 31 January, it is currently still in it’s agreed-upon transitional period until the end of this year. The two sides are now negotiating a trade deal which will clarify their future relationship. At the moment, neither the public nor the CBD industry know what to expect. However, experts project that Brexit might, in fact, offer a golden opportunity for CBD businesses.

Sheffield, UK, September 2020 – CBD is one of the most common chemical compounds found in the cannabis plant. It is classed as a cannabinoid, along with THC. However, CBD, on the contrary to its cousin THC, does not cause the ‘high’ often associated with cannabis.

It is a naturally occurring chemical known for its supposed health and wellness benefits. Among its reported benefits are its ability to reduce feelings of anxiety and depression, its anti-inflammatory properties, and its ability to ease the symptoms of spasticity-related conditions.

That is why the looming decision of the European Commission (EC) to class CBD as a narcotic, rather than a novel food, has sparked fury in the industry.

According to the UK government, “novel foods are foods which have not been widely consumed by people in the UK or EU before May 1997. This means that the foods don’t have a history of consumption.”

An EC spokesman told Food navigator that they had “doubts about CBD”:

“For the moment, the preliminary analysis says that it could not be qualified as food but it’s not a final decision.”

So, long story short, if it’s classed as a narcotic, it won’t be able to get through the EU’s Novel Food process – cutting off hundreds of products and businesses from the market.

What is it going to be then?

It must be stated that the UK, as a member of the EU, has adopted a number of EU rules and regulations. Brexit would mean that, depending on the agreement, this won’t be the case after 31 December 2020.

Although some believe Brexit will hit the UK economy hard, others are convinced that the CBD industry could be one of the few that clearly benefit from the country’s departure from the trade block.

A Spokesperson for The Association for the Cannabinoid Industry told Canex that the UK Food Standards Agency (FSA) would have their own novel food authorisation process, therefore, CBD businesses would be able to be granted license much quicker.

They told us: “It could offer a golden opportunity. The most direct change will be the UK removing itself from commitments to the European Commission.

“EFSA has just announced that they are putting all novel foods applications on hold until the EC decides whether CBD should be classified as a narcotic. If they do, CBD would become a controlled substance in Europe.

“FSA and the UK Home Office say they do not think CBD is a narcotic so this offers a great opportunity to companies wishing to sell in the UK.”

Liz McCulloch, Director of Policy for Volteface, added:

“If the UK continues to take the view that CBD is a novel food, while the EU treats it as a narcotic, this will pave the way for the UK to have one of the more liberal regimes in Europe and a comparatively lucrative market.

“The government should capitalise on this opportunity by introducing policy reforms that will build a domestic CBD extraction industry and make the UK a hub of research and development.”

Freedom

Experts believe that, if the FSA said that CBD was indeed a novel food, then it would see the UK a global leader of the CBD market post-Brexit.

The ACI spokesperson said: “The main point is that the CBD has to have a novel foods validation from the FSA by 31 March 2021. Without that, the raw material or finished product would not be legal to sell in the UK.

“After Brexit, the UK will have more control over its domestic hemp market, ideally CBD products sold in the UK and beyond will also be grown here in the future.”

After all those years of debating and fighting, there might be an area that would benefit from Brexit.

It may not be 100% certain, and there is still an awful lot to do until 1 January 2021, but if the UK plays their cards right, the CBD industry might be able to flourish in the upcoming age of uncertainty.

About Company:

#UK-based portal for CBD news

0 notes

canexuk · 5 years ago

Text

FSA Announces Novel Food Guidelines for UK CBD Businesses

Over a year after the European Commission announced CBD’s classification as a Novel Food, the UK’s Food Standards Agency (FSA) has revealed a new deadline for UK CBD businesses to comply with Novel Food regulation.

Sheffield, UK, April 2020 – Over a year after the European Commission announced CBD’s classification as a Novel Food, the UK’s Food Standards Agency (FSA) has revealed a new deadline for UK CBD businesses to comply with Novel Food regulation.

Food and drinks businesses that incorporate cannabidiol in their products have been told to reach compliance by March 31st 2021. Businesses that have not been granted approval by this date will face their products being removed from shelves.

Until this time, companies can continue to sell their existing products, provided they are not incorrectly labelled. However, the FSA has stated that “no new CBD extracts or isolates should be sold until they have the necessary authorisation.”

The Novel Food application deadline applies to all CBD businesses based and operating in England, Wales, and Northern Ireland. Applications in Scotland will be processed by Food Standards Scotland.

CBD in the UK

The CBD market in the UK (and the rest of the world) has rocketed over the last few years. Last June, the Centre for Medicinal Cannabis (CMC) reported that up to 6 million people in the UK had tried a product containing the Cannabis derivative. CBD products have continued to grow in popularity in the UK despite January 2019’s Novel Food classification casting some uncertainty over the industry,

However, the industry has earned its fair share of criticism following the publication of the CMC’s ‘CBD in the UK‘. The report found that a significant proportion of CBD markets on the market were incorrectly labelled – in some cases containing levels of ingredients that would technically make them illegal.

There have been a series of calls from various bodies to improve regulation on the industry to increase transparency and reliability. The CMC even launched its own cannabinoid regulatory body – the Association for the Cannabinoid Industry (ACI).

Dr. Andy Yates, Pharmacy Lead at the ACI, claimed:

“The FSA have today provided us with the regulatory clarity that the industry and consumers have been crying out for.”

The Food Standards Agency has also provided a collection of guidelines for CBD companies to incorporate into their product labelling. This included recommended dosages for healthy individuals, and warnings against use for pregnant, breastfeeding or taking medications.

UK CBD businesses are reminded that FSA authorisation of their products “is the only route to compliance for these CBD products” under Novel Food regulation.

About Company:

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

Here in the UK, the Cannabidiol industry is on the point of significant change, with calls coming from independent agencies for regulatory reform. Canex brings you all the information you need to know to the same place, making it easier to keep up to date than ever before.

#UK-based portal for CBD news

0 notes

canexuk · 4 years ago

Text

Czech Republic Medical Cannabis – New Cultivation and Export Rules

The Czech government has released details of new cultivation and export rules expected to be introduced in the country’s medical cannabis sector. The new rules will stem from a Bill aimed at reforming the Czech Republic’s Act on Addictive Substances.

If approved, the bill is expected to lead to an increase in cultivation and export licenses for medical cannabis in the country. Medical cannabis has been legal in the Czech Republic since 2013. However, current rules have received criticism for stifling easy access to cannabis medications.

The country has also struggled to keep up with the demand for differing preparations of medical cannabis products. Original domestic harvests of medical cannabis were of the same strain of products imported from Bedrocan in the Netherlands. This meant that a limited number of Czech patients have so far benefitted from medical cannabis.

However, despite a lack of diversity in products, availability has gradually improved since the introduction of legalisation. The number of prescribing doctors and pharmacies providing medical cannabis products has gradually increased – up from 41 pharmacies in 2018 to 90 in 2020.

In addition, the State Institute for Drug Control nearly 16kg of medical cannabis was sold between January and April 2020. This is around the same amount sold in the whole od 2019.

Czech MP for the country’s Pirate Party, TomášVymazal, stated:

“For the first time, members of Parliament will have to deal with the legalization of cannabis, which has so far been parked among stacks of pending proposals. Now it is up to us to convince MPs to deal with legalization in committees… “

This new Bill, which will be voted on by the Czech Parliament, will aim to take this progress even further. Currently, there is only one domestic grower of medical cannabis supplying products for the sector. The proposed amendments will make it easier for cultivation licenses to be granted, improving diversity and supply in the sector.

In October 2019, the Czech government announced plans to subsidies the cost of medical Cannabis from public health insurance. The plan meant that patients would be reimbursed for up to 90% of the cost of their medical cannabis prescriptions.

If approved by MPs in parliament, implementation of the new rules would be expected by mid-2021.

About Company:

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

#medical cannabis products.#UK-based portal for CBD news

0 notes

canexuk · 5 years ago

Text

Government Announces Improved Patient Access to Medical Cannabis

Sheffield, UK– Companies in the UK will now be able to order more stocks of medical cannabis products from abroad. Previously, orders had to be made on a patient-by-patient basis, meaning many patients faced delays of months.

Crucially, companies will also be permitted to hold stocks for future prescriptions. This should improve waiting times for medical cannabis access to just days.

Health Secretary Matt Hancock announced:

“The changes made today are a tremendous step towards improving the supply of cannabis-based medicinal products … But we still have a long way to go.”

Campaigners welcomed the news but echoed the Health Secretary’s feeling that more still needs to be done. As clinical research and evidence around medical cannabis remain limited, the number of prescriptions for the products is expected to remain low.

The situation is further aggravated by a lack of specialist doctors in the UK. Cannabis research company Prohibition Partners claims that, out of the 180,000 doctors in the UK, only a handful have been educated in the endocannabinoid system.

Dr. Andy Yates, Pharmacy Lead at the Centre for Medicinal Cannabis, applauded the decision.

He stated: “We are grateful that the government has listened to the valid concerns expressed by our members and responded with measures that will immediately improve access to these novel medicines and accelerate clinical understanding of their use.”

Medical Cannabis in the UK

Specialist doctors in the UK can prescribe medical cannabis products to patients who suffer from rare forms of epilepsy and multiple sclerosis. However, recommendations published by NICE in November indicate that cannabis products may also be considered for other health conditions.

Despite calls for more research, only a small number of cannabis-based medications are licensed in the UK. These include Epidyolex, which has been shown to dramatically reduce seizures in treatment-resistant epilepsy; Sativex, used as a treatment for multiple sclerosis; and Nabilone, which can help with chemotherapy-induced nausea.

Would you like to know the results of our polls? Please complete the data request form by clicking here.

About Company:

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

#UK-based portal for CBD news

0 notes

canexuk · 4 years ago

Text

Patients Able to Access Medical Cannabis In Ireland From Today

From today, some patients in Ireland will be able to access to medicinal cannabis through the health service. However, similarly to in the UK, the cannabis-based products will only be available for patients with a limited number of conditions.

Sheffield, UK, February 2021 – The Minister for Health, Stephen Donnelly, announced funding for the programme which will see specialist clinicians able to prescribe medical cannabis for a handful of conditions. Patients may be prescribed cannabis-based medications for muscle spasms associated with multiple sclerosis, chemotherapy-induced nausea, and severe forms of epilepsy.

The measures around access to the medicines echo those currently in place in the UK, where medical cannabis was legalised in 2018.

In a statement, Mr Donnelly stated: “One of the improvements in our Health Services that will benefit from this extra funding is the Medicinal Cannabis Access Programme which has been added to the HSE Service Plan for 2021.

“The purpose of this Programme is to facilitate compassionate access to cannabis for medical reasons, where conventional treatment has failed.”

Governments in Europe are increasingly coming under pressure to expand medical cannabis programmes as the public adopts a more liberal attitude to the drug. However, most European countries are yet to establish a medical cannabis sector like those seen in Canada and some US states.

Ireland’s Minister for Health, Stephen Donnelly, continued:

“Ultimately it will be the decision of the medical consultant, in consultation with their patient, to prescribe a particular treatment, including a cannabis-based treatment, for a patient under their care.”

Ireland’s new medical cannabis programme is expected to be similar to that of the UK, where access to medicines through the NHS have been few and far between. Instead, many patients access their medicine through private cannabis clinics around the country.

Cannabis flower will remain prohibited for both medical and recreational purposes, with only licensed cannabinoid-based pharmaceuticals being available through the medical cannabis programme.

Doctors are yet to adopt medical cannabis as a routine option, even for conditions approved by the government. This is often put down to a lack of clinical evidence demonstrating the efficacy of the products.

About Company:

#medical cannabis was legalised

0 notes

canexuk · 4 years ago

Text

United Nations Votes to Remove Cannabis from List of Hard Drugs

United Nation’s Commission for Narcotic Drugs has voted to reschedule cannabis, effectively removing it from a list including ‘hard’ drugs, such as heroin.

Sheffield, UK, January 2021 – United Nation’s Commission for Narcotic Drugs has voted to reschedule cannabis, effectively removing it from a list including ‘hard’ drugs, such as heroin. With the exception of one EU member state, Western countries, in general, voted for the proposal. While cannabis advocates are welcoming the decision, some warn that there is still a lot of work ahead.

Almost two years after the World Health Organisation (WHO) recommended the rescheduling of cannabis and cannabis-related substances, 53 member states of the Commission for Narcotic Drugs held a vote to dismiss or approve the recommendation on Wednesday.

According to International Drug Policy Consortium, the commission was to acknowledge “cannabis’ medicinal usefulness” and consider the removal of “extracts and tinctures of cannabis” from the 1961 Convention.

Prior to the vote, cannabis and cannabis resin were listed as Schedule IV drugs alongside so-called hard drugs, such as heroin and other opioids.

In the vote, 27 member states supported the proposal, while 25 were against and one, Ukraine, was absent. Interestingly enough, only one EU country, Hungary, went against the rescheduling.

However, cannabis remains to be listed as a Schedule 1 drug, which means it is still regarded as “a substance with addictive properties, presenting a serious risk of abuse.”

Ann Fordham, Executive Director of the International Drug Policy Consortium, was not entirely satisfied when issued an official response: “We welcome the long-overdue recognition that cannabis is a medicine.

“However, this reform alone is far from adequate given that cannabis remains incorrectly scheduled at the international level.

“The original decision to prohibit cannabis lacked scientific basis and was rooted in colonial prejudice and racism.

“It disregarded the rights and traditions of communities that have been growing and using cannabis for medicinal, therapeutic, religious, and cultural purposes for centuries and has led to millions being criminalised and incarcerated across the globe.

“The review process has been a missed opportunity to correct that historical error.”

About Company:

0 notes

canexuk · 4 years ago

Text

Thailand to Allow Cannabis Use for Personal and Healthcare

In a landmark decision, Thailand is to allow the use of most parts of cannabis and hemp in cosmetics and food. Additionally, it is reported that individuals and businesses will be able to utilise hemp seeds and seed extract, as well as CBD.

Sheffield, UK, December 2020 – After the Thai parliament approved cannabis for medical and research purposes in 2018, Thailand became the first country in the Asian region to partly amend its rather strict drug policy.

Essentially, cannabis was banned in 1930, although the drug had been a well-known and popular medicine for centuries in the country. It has reportedly helped farmers struggling with muscle pains and women to reduce labour pain.

Back in 2018, Chairman of the Government Pharmaceutical Organisation Dr Sophorn Mekthon said the aim was to grant access to medicinal cannabis to those after the alternative treatment.

Now, according to Public Health Permanent Secretary Kiattiphum Wongrajit, the government plans to ease the law so that regulated business will be able to use some part of the plant in the health sector.

For instance, the government’s decision will allow them to use cannabis and hemp in order to create cosmetics and food products.

Bangkok Post reported that the Thai Narcotics Control Committee had agreed to remove “the leaves, branches, stems, trunks, bark, fibre and roots of cannabis and hemp from the government’s narcotics list.”

Dr Kiattiphum’s announcement means that hemp seeds and seed extract, as well as CBD and a limited amount of THC, will be allowed to be utilised by regulated business in the country.

The permitted parts and content will be required to come from previously authorised producers. This includes government organisations responsible for “medical and research tasks”, medical practitioners, universities, domestic firms and community cooperatives.

The next step is to see the Food and Drug Administration draft a new public health regulation before the public health minister approves it.

About Company:

We are Canex – the leading UK-based portal for CBD news With the CBD industry exploding all around the world, we aim to bring you everything you need to know – from both home and abroad. The CBD industry has become one of the fastest growing health and wellness industries in recent years. We provide the most up-to-date information about the industry, in order to keep the general public well-educated in line with this growth.

#government’s decision will allow them to use cannabis and hemp

0 notes

canexuk · 4 years ago

Text

Amazon to Launch UK-only CBD Product Platform Project

Sheffield, UK, November 2020 – Businesscann reported that Amazon would allow a number of CBD businesses to sell their products in the UK. Amazon pointed out in a statement that selling CBD products is illegal on their website, except for those participating in the invite-only pilot.

Siân Phillips, Managing Director of the Cannabis Trades Association (CTA), was happy when asked about Amazon’s presence in the CBD market.

She said: “From the perspective of the CTA it opens up the UK market place for Hemp and CBD oil sellers and yet another platform for legitimate and compliant companies.

“On the negative side, will Amazon’s due diligence ensure that sellers are reputable, have products compliant to UK regulations – i.e. no medicinal claims, correctly labelled, etc – and are able to confirm their supply chain as being Novel Food approved after March 2021?

“We have been in touch with Amazon and are awaiting contact from their policy department.”

Leila Simpson, Head of External Affairs, at the UK Association for the Cannabinoid Industry, told Businesscann that they predicted more major retailers being involved after Amazon’s decision, and it was a “good for the industry.”

According to the latest reports, Amazon found the pilot to be a great success, so it might open the window for a wider range of retailers in the UK as early as in the next few weeks or 2021.

Officials at Amazon are now making a checklist for businesses interested in joining to meet.

First and foremost, as Businesscann understood, applications must be submitted to EFSA (European Food Safety Authority) 1st January, when new Brexit regulations are scheduled to come into force.

Also, the products the applicants seek to sell should adhere to the UK’s Novel Food regulations.

Stuart McKenzie, CEO of Reakiro, said: “Once the door is open, we understand it may take a few months for product owners to registrar themselves online as long as they can satisfy the Amazon terms and conditions for listing as a CBD vendor.

“At this stage, we understand this will be a UK-only market for Amazon. The Amazon people are learning more about CBD, and there is a feeling among them that it could be really big.

“With Amazon on board, it will surely allow consumers much easier access to CBD and ultimately help millions of people live a healthier and happier life.”

About Company:

We are Canex – the leading

UK-based portal for CBD news

. With the CBD industry exploding all around the world, we aim to bring you everything you need to know – from both home and abroad. The CBD industry has become one of the fastest growing health and wellness industries in recent years. We provide the most up-to-date information about the industry, in order to keep the general public well-educated in line with this growth.

0 notes

canexuk · 5 years ago

Text

What Will the UK CBD Industry Look Like Post-‘Brexit’?

Throughout the UK’s membership of the European Union, certain laws and restrictions have been adopted. Along with many other things, this is likely to change after the completion of Brexit. Expert economists have repeatedly claimed that Britain’s exit from the EU will most likely lead to the slow-down of economic growth and industry.

However, many in the CBD industry believe that theirs will be one of the few industries that won’t be negatively affected by Brexit.

In December 2019, Cannabis business analysts, Prohibition Partners, published ‘The UK Cannabis Report’. The report outlines the ins-and-outs of different aspects of the different Cannabis sectors – medicinal, recreational, and CBD.

Prohibition Partners point to the possibility:

“[Once the UK leaves the EU,] the door may be opened to introduce edible brands”.

This is an area of the CBD industry that currently faces some uncertainty. Although the UK has not, up to now, adopted the EU’s ruling as a Novel Food – effectively requiring companies to gain licensing in order to incorporate the ingredient in foods – industry bodies have remained cautious.

The European Commission ruled in January 2019 that cannabidiol (CBD) is a Novel Food. This refers to an ingredient that was not consumed to a significant extent prior to 15th May 1997. The official stance of the EU is that companies must procure Food Safety certification.

However, the ruling was not enforced strictly in the UK and other European countries.

Nevertheless, at the end of 2019, the Centre for Medicinal Cannabis (CMC) launched the Association for the Cannabinoid Industry (ACI), which aims to provide an industry standard for CBD companies in the UK. As part of their framework, the ACI works to gain FSA certification for its members – making them compliant with Novel Foods requirements.

Further, some people believe Brexit may even open up increased opportunities for the UK CBD industry. Namely, the possibility of developing an industry similar to that in Switzerland, where the CBD sector is booming.

Former Policy Lead at the CMC and government advisor, Blair Gibbs, stated at the CBD Europe Expo, last year:

“Brexit gives us a chance to diverge (from European regulation) and gain a competitive edge.”

This remains to be seen, as the UK currently enforces stricter rules on the cultivation of hemp and processing of CBD, than in many other EU countries.

About Company:

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

#UK-based portal for CBD news.

0 notes

canexuk · 5 years ago

Text

Genuine CBD Products - Revealing CBD Scams on eBay and Amazon

Sheffield, UK, May 2020 – Surprisingly, CBD products are banned by both platforms, creating the perfect environment for scammers. In the absence of genuine CBD, snake oil salespeople have flooded these sites with products that look like CBD oil, are priced like CBD oil but contain no CBD.

Online retailers ‘For the Ageless’ investigated these products to find out if CBD could be bought from either site. Their findings gave them a unique insight into avoiding a scam and selecting quality oils.

CBD products on Amazon

On Amazon’s UK site, the sellers’ guidelines ban the sale of all products containing; “Cannabinoids including Cannabidiol (CBD) and Tetrahydrocannabinol (THC)”. However, if you do search for CBD on Amazon, you will find hundreds of products that look remarkably like CBD oil.

As with genuine CBD oils, they show a value in mg like 1000mg, or a percentage like 5%, but when you look closer it doesn’t refer to anything. Most call themselves things like ‘Hemp oil drops’ or ‘Enriched Hemp Oil Extract’.

In their research, For the Ageless discovered that on the first results page for the term ‘CBD oil’:

· 70% of the products cost more than £10 for between 10 and 30mls.

· None of them mentioned containing any CBD and appeared to be consisting mainly of hemp seed oil or blend of an unspecified hemp extract.

· 42% of these products were listed with strong implications of health benefits like ‘for anxiety’ and ‘for chronic pain’.

It is likely that most of these oils contain little more than hemp seed oil. This, while having several nutritional benefits, contains no CBD and can be bought for about £7 for 500mls.

When they investigated further, they found that several of these products had rave reviews. Although, below those they found the true story:

“Please don’t be misled as I was – this is not CBD oil, as the listing and answers to questions imply.”

“Falsely advertised as being close to CBD oil but is, in fact, hemp oil.”

“NOT CBD, I REPEAT, NOT CBD”

CBD products on eBay

eBay’s approach to CBD is slightly more complicated. They also ban all CBD products, but they seem confused when asked why. When they were questioned by their customers they responded:

“We do acknowledge your point about the product being legal; however, we haven’t received any such information from the government bodies, including the same.”

The same search term, ‘CBD oil’, yielded 46 results on the first page, 91% of which displayed an amount in mg that, on inspection, didn’t relate to anything. These were predominantly 10ml to 30ml bottles of oil labelled as ‘hemp extract’, ‘hemp oil’ or ‘hemp oil extract’.

Unlike Amazon, on eBay there were some products that did display mentions of CBD. One product labelled as hemp oil included a description of ‘CBD oil solution’ but showed no evidence to indicate that it contained any CBD at all. It is likely that most of these products are mostly hemp seed oil or something similar.

How can I find genuine CBD oil?

Many people assume that eBay and Amazon are trusted sites, and while most of these items aren’t illegal, they are definitely scams. To find out if it is possible to identify genuine CBD oils, we spoke to Daniel, co-founder of for the Ageless:

Following your research, do you think it is ever advisable to purchase CBD oil from Amazon or eBay?

No, unless either site makes significant changes to their guidelines, it is unlikely that you will find good-quality CBD oil there.

What should you look out for to identify a scam?

Look carefully at the label and product description. The scams often have very vague descriptions and don’t call themselves ‘CBD oil’ but use phrases like ‘hemp drops’. CBD oils usually explicitly say how much CBD they contain like ‘300mg CBD’ but scams show a generic amount such as ‘300mg’ with no indication as to what it refers to.

How can you be sure that you’re buying genuine, high-quality CBD products?

Always start with a retailer who has a good reputation. This might be a recommendation from a friend, good reviews on Trustpilot or they could be a member of an industry body like CannaPro or the Cannabis Trades Association.

Once you’ve found a retailer, look for third-party certificates of analysis. These are documents that display the results of lab tests carried out by an independent company. They should be easy to find on the seller’s site and will show you how much of each cannabinoid, including CBD and THC, was detected in the sample.

This will help you verify that any claims on the label of the product are true. We strongly advise that if a company doesn’t let you see the certificates, don’t buy from them.

Another thing to look out for is that every claim like ‘0% THC’ or ‘farmed organically’ should be backed up with evidence. You should expect to see the organic certification or corresponding lab results.

Finally, ask them if there’s anything you’re unsure about. Companies selling genuine, high-quality products will be happy to prove this to you.

About Company:

From product news, reviews and guides; to legislation changes, industry updates and guides through the ongoing studies of the substance, Canex has it covered.

0 notes